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Dietary peroxisome proliferator-activated receptor (PPAR)γ ligands, linoleic acid (LA) and conjugated linoleic acid (CLA),
showed anticancer eﬀects in colorectal carcinoma cells. LA is metabolized by two pathways. Cyclooxygenase (COX)-2 produces
procarcinogenic prostaglandin E2, whereas 15-lipoxygenase (LOX)-1 produces PPARγ ligands. The 15LOX-1 pathway, which is
dominant in colorectal adenomas, was downregulated and inversely COX-2 was upregulated in colorectal cancer. LA and CLA
inhibited peritoneal metastasis of colorectal cancer cells in nude mice. The inhibitory eﬀect was abrogated by PPARγ antisense
treatment. A continuous LA treatment provided cancer cells quiescence. These quiescent cells formed dormant nests in nude mice
administrated LA. The quiescent and dormant cells showed downregulated PPARγ and upregulated nucleostemin. Thus, short-
termexposure to dietaryPPARγ ligands inhibits cancer metastasis,whereas consistent exposure to LA provides quiescent/dormant
status with possible induction of cancer stem and/or progenitor phenotype. The complicated roles of dietary PPARγ ligands are
needed to examine further.
Copyright © 2008 Hiroki Kuniyasu. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Colorectal cancer is the third most common malignant
neoplasm worldwide and the third leading cause of cancer
deaths in Japan [1]. The frequency of colorectal cancer
in Japan doubled in the last three decades according
to the alteration of life style from Japanese to Western
[2]. Especially, the increase in fat intake and decrease in
ﬁber intake have been regarded as the most important
nutritional inﬂuence on colon cancer development [3,
4]. In this review, we focused on the fatty acids, which
possess ligand activity for peroxisome proliferator-activated
receptor (PPAR)γ in foods. PPARγ is activated by endoge-
nous secreted prostaglandins and fatty acids. 15-deoxy-
δ(12,14)-prostaglandin J2 is a strong endogenous ligand
of PPARγ [5]. Linoleic acid (LA) is one of the essential
fatty acids, which we must intake from food. Metabolic
products of LA, such as 9-hydroxyoctadecadienoic acid (9-
HODE), 13-hydroxyoctadecadienoic acid (13-HODE), and
13-oxooctadecadienoic acid (13-OXO), are known as PPARγ
ligands [6]. Conjugated linoleic acid is a stereoisomer of LA
[7]. CLA is contained in beef, lamb, and also in vegetable oils
[8]. Roles of these dietary PPARγ ligands on PPARγ activa-
tion are not still unclear. Colorectal cancer is a good model
for inﬂuence of nutritional factors to cancer development
and progression [9, 10]. In this review, roles of LA and CLA
for colorectal cancer progression and therapeutic possibility
are discussed as dietary PPARγ ligands.
2. METABOLIC PATHWAYS OF LINOLEIC ACID
Prostaglandins (PGs) are bioactive lipids derived from
the metabolites of membrane polyunsaturated fatty acids
(PUFAs), and play important roles in a number of biolog-
ical processes [11]. Cyclooxygenases-2 (COX-2)-dependent
overproduction of PGE2 is hypothesized to be an important
part of sustained proliferative and chronic inﬂammatory
conditions [12, 13]. Several in vivostudies hypothesize that
ah i g ha m o u n to fω-6 PUFA such as LA might enhance
colorectal carcinogenesis via stimulation of colonic epithe-
lial cell proliferation [14–17]. In fact, rats treated with
a genotoxic agent, azoxymethane (AOM), and fed a diet
supplemented with LA develop more tumors than those
treated with AOM alone [18].2 PPAR Research
The oxidative metabolites of LA, in particular, 9-HODE,
13-HODE, and 13-OXO, have biological eﬀects as a PPARγ
ligand [6]. CLA, a strong ligand for PPARγ, has a substantial
anticarcinogenic eﬀect [8, 19]. Synthesized PPARγ ligands
including troglitazon have been shown to be eﬀective
chemopreventive agents in a rat model of carcinogenesis and
in AOM-induced colon cancer in mice [20]. If LA provides
PPARγ ligands, LA might act as an anticarcinogenic agent.
Arachidonic acid is a fatty acid and a component of
lipidmembranes,andalsoamajorsubstrateforlipoxygenase
enzymes. 15lipooxygenase-1 (15LOX-1) is known for its
anti-inﬂammatory properties and has a profound inﬂuence
on the development and progression of cancers [21, 22].
Recent studies show that ligand activation of PPARγ in
colorectal cancer cells attenuates colonic inﬂammation and
causes a reduction growth via the induction of apoptosis
[23, 24]. Furthermore, it has been reported that a number
of metabolites generated by 15LOX-1 can function as
endogenous activators and ligands for PPARγ [25, 26]. We
conﬁrmed the anticarcinogenic eﬀect of LA by in vitro
transformation assay using a rat intestinal cell line, IEC6,
which expressed 15LOX-1, but not COX2. LA treatment
inhibited AOM-induced transformation in IEC6 cells [27].
Many literatures reported that PPARγ possesses an anti-
carcinogenic eﬀect in colorectal cancer [20]. Moreover, a
decrease in PPARγ expression is associated with cancer
metastasis [28, 29]. Inhibitory eﬀect of PPARγ to cancer
metastasis is reported in several cancers, such as nonsmall
cell lung cancer, colon cancer, thyroid cancer, and breast
cancer [30–33].
3. SWITCHING OF LA METABOLIC PATHWAYS
FROM 15LOX-1 TO COX-2 IN COLORECTAL
CANCER DEVELOPMENT
Inhibitory eﬀect of LA on intestinal epithelial cell trans-
formation elucidated above suggests that 15LOX-1 LA
metabolism suppresses colon carcinogensis [27]. We next
focused on the dual roles of LA in human colon cancer
development. Expression of 15LOX-1 and COX-2 was exam-
ined in human colon adenoma and carcinoma to elucidate
the balance of the two LA metabolic pathways in malignant
transformation of human colon epithelium.
We examined the expressions of COX-2 and 15LOX-1
in 54 adenomas, 21 carcinoma-in-adenoma lesions, and 36
serosa-invading advanced carcinomas in the colon [34]. We
examined 15LOX-1 mRNA and COX-2 protein by in situ
hybridization and immunohistochemistry, respectively. In
the nonpathological colon mucosa, which expressed 15LOX-
1 but not COX-2, proliferation of colon epithelial cells was
controlled at constitutive levels. 15LOX-1 mRNA was found
in 96% of adenomas, 43% of adenoma in carcinoma-in-
adenoma lesions, and 10% of carcinoma in carcinoma-in-
adenoma lesions, but not in advanced carcinoma (P<
.0001). In contrast, COX-2 production was found in 11%
of adenomas, 52% of adenoma in carcinoma-in-adenoma
lesions,71%ofcarcinomaincarcinoma-in-adenomalesions,
and 92% of advanced carcinoma (P<. 0001). Concurrence
of COX-2 induction with 15LOX-1 downregulation was
found in 6% adenomas, in 33% adenoma components,
and 71% carcinoma components of carcinoma-in-adenoma
lesions (all mucosal cancer), in 89% cases in nonmetastatic
serosa-invading carcinomas, and in 100% cases of nodal
metastasized carcinomas. Our data showed that induc-
tion of COX-2 expression and downregulation of 15LOX-
1 were sequentially increased from adenomas, adenoma
components, and carcinoma components in carcinoma-in-
adenoma lesions, to invasive carcinomas. Interestingly, low
grade-adenomacomponentswithincarcinoma-in-adenoma
lesions showed COX-2 expression and 15LOX-1 downregu-
lation at more frequency than low grade-adenomas, which
suggests that the biological property is diﬀerent in the same
histological atypia. In contrast, high grade-adenoma com-
ponents showed no diﬀerence from high grade-adenomas
in expressions of COX-2 and 15LOX-1, which suggests
that high grade-adenomas might already possess malignant
potential as high as adenoma components in carcinoma-in-
adenoma lesions. This sequential alteration of concurrence
of COX-2 induction with 15LOX-1 downregulation possibly
shows close association of the switching of LA-metabolizing
pathways with colon cancer development and progression.
15LOX-1 is revealed as an apoptosis inducer in human
cancers and inhibits cancer progression. The reduction of
15LOX-1 and the isoform 15LOX-2 is correlated with the
disease progression of breast cancer and the poor clinical
outcome [35]. Induction of 15LOX-1 provides apoptosis in
oral cancer [36]. 15LOX-1 expression is downregulated in
colon adenomas, and ectopic expression of 15LOX-1 induces
apoptosis in Caco-2 colon cancer cells [37].
In expression of 15LOX-1, inﬂammatory cytokines
play an important role. Interleukin (IL)-4 and IL-13
induce 15LOX-1 expression via Jak2/Tyk2/Stats pathway
[36, 38–40]. In prostate cancer, ratio of ω-3/ω-6 fatty acids
is associated with expressions of 15LOX-1 and COX-2
[41]. 15LOX-1 induction by nonsteroidal anti-inﬂammatory
drugs(NSAIDs),suchassulindacsulfone,providesapoptosis
in SW480 colon cancer cells. Sulindac sulfone inhibits GMP
(cGMP)-phosphodiesterases and activates protein kinase
G, which enhances 15LOX-1 expression transcriptionally
[42]. GATA-6 transcriptional factor is involved in NSAID-
induced 15LOX-1 induction in RKO and DLD-1 colon
cancer cells [43]. GATA-6 activates 15LOX-1 promoter in
Caco-2 colon cancer cells but not in the cells induced
diﬀerentiationbysodium-butyrate[44].Thesearesupported
by conventional NSAIDs activates PPARγ [45]. COX-2
expression also involves Jak2/Stats pathway and nuclear
factor (NFκB) [46–48]. Activation of PPARγ downregulates
COX-2 expression by inhibition of NFκBa n da c t i v a t o r
protein (AP)-1 [49]. This negative regulation of COX-2
expression by PPARγ activation might be one of the mecha-
nisms of reversal expressions between 15LOX-1 and COX-2.
Furthermore, promoter DNA methylation is responsible for
silencing 15LOX-1 expression, which is reversed by 5-aza-2-
deoxycytidine treatment [50, 51]. The epigenetic alteration
might be a trigger to switch 15LOX-1 repression and
COX-2 upregulation along with malignant transformation
and disease progression in colorectal cancer. Thus, switching
of LA metabolism from 15LOX-1 to COX-2 is thought to beHiroki Kuniyasu 3
a common mechanism to escape from antitumoral eﬀect of
LA.
4. ANTITUMOR EFFECT OF CLA
We next argue the eﬀect of CLA, which is an isomer of
linoleic acid and is established as a PPARγ ligand without
metabolization by 15LOX-1. CLA is a natural content of
some foods, such as beef, lamb, and also vegetable oils
[8]. CLA is one of essential fatty acids, which possesses
characteristic bioactive properties [8]. CLA is composed of
positional- and stereoisomers of octadecadienoate (18:2).
Chemoprotective properties of CLA are reported in experi-
mental cancer models and in vitro examinations [8, 19]. Dif-
ferently from LA, CLA is not a precursor of prostaglandines.
CLA activates PPARγ as a ligand [7, 52]. Through activation
of PPARγ, CLA might act as an antimetastatic agent
as well as an anticarcinogenic agent. We examined the
antimetastatic eﬀect of CLA on peritoneal dissemination
[53]. Cell growth of MKN28 human gastric cancer cells and
Colo320 human colon cancer cells was suppressed by CLA in
a dose-dependent manner with an increment in apoptosis.
CLA signiﬁcantly inhibited invasion into type IV collagen-
coated membrane of MKN28 and Colo320 cells. CLA-
induced growth inhibition was recovered by the exposure
to antisense S-oligodeoxynucleotides (ODN) for PPARγ in
both cell lines. BALB/c nu-nu mice were inoculated with
MKN28 and Colo320 cells into their peritoneal cavity, and
administrated with CLA intraperitoneally (weekly, 4 times).
CLA treatment did not aﬀect food intake or weight gain
of mice. CLA treatment signiﬁcantly decreased metastatic
foci of both cells in the peritoneal cavity. Survival rate
in mice inoculated with MKN28 or Colo320 cells was
signiﬁcantly recovered by CLA treatment. PPARγ initiates
transcription of genes associated with energy homeostasis,
cell growth, and anti-/proinﬂammatory eﬀect [24, 54–57].
Protein production in MKN28 and Colo320 cells treated
with CLA showed a decrease in epidermal growth factor
receptor (EGFR) and transforming growth factor (TGF)-
α and an increase in Bax. Our results showed that CLA
inhibits cell growth and invasion, and induces apoptosis in
cancer cells. Our data are supported with the reports, which
indicate that PPARγ downregulates EGFR, and upregulates
Bax, p21Waf-1, and E-cadherin, which are associated with
antiproliferative, proapoptotic, and prodiﬀerentiation eﬀects
[33, 58–60].
We also reported the tumor suppressive eﬀect of CLA
on established peritoneal tumors using a syngeneic mouse
peritoneal metastasis model [61]. C57BL6 mice were inoc-
ulated with LL2 cells into their peritoneal cavity. Two
weeks after the inoculation, colonized peritoneal cancer
foci (2.2 ± 0.4 mm in diameter) were treated with CLA
administrated intraperitoneally (600pmol/mouse, weekly,
twice). CLA treatment decreased the number of peritoneal
tumors to 26% of that in untreated mice (P<. 0001). CLA
treatment also decreased size of peritoneal tumors to 27% of
that in untreated mice (P<. 0001). In CLA-treated tumors,
proliferating cells were decreased (P<. 0001), whereas
apoptotic cells were increased (P<. 0010). CLA-treated
LL2 tumors showed decrease in PPARγ and EGFR proteins,
and increase in Bax protein in comparison with untreated
tumors.
5. ANTITUMOR EFFECT OF LINOLEIC ACID
We conﬁrmed antimetastatic eﬀect of PPARγ by CLA in gas-
tric and colon cancer cells. We next examined antimetastatic
eﬀect of LA.
The eﬀect of LA on peritoneal metastasis was exam-
ined using in vitro treatment of cancer cells and mouse
peritoneal metastasis models as well as CLA examination.
Firstly, cell growth of MKN28 human gastric cancer cells
and Colo320 human colon cancer cells were suppressed
by LA in a dose-dependent manner with increment of
apoptosis. LA signiﬁcantly inhibited invasion into type
IV collagen-coated membrane of MKN28 and Colo320
cells (P<. 05). The inhibition of growth and invasion
and the induction of apoptosis by LA were abrogated by
exposure to antisense S-ODN for PPARγ. Moreover, the
decrease in 15LOX-1 expression by exposure to antisense
S-ODN for 15LOX-1 suppressed the inhibition of growth
and invasion and the induction of apoptosis by LA. LA-
induced growth inhibition was recovered by the exposure
to antisense S-ODN for PPARγ or 15LOX-1. BALB/c nu-nu
mice inoculated with MKN28 and Colo320 cells into their
peritoneal cavities were administrated IP with LA (weekly,
4 times). The LA treatment signiﬁcantly diminished the
number of metastatic foci of both cells in the peritoneal
cavity (P<. 05). Protein production in MKN28 and Colo320
cells treated with LA showed a decrease in EGFR and an
increase in Bax. PPARγ activation is reported to decrease
EGFR expression and increase Bax expression [58, 60]. Our
data suggest that LA possesses the same mechanism to
CLA of PPARγ ligand; however, its eﬃcacy was 103 times
weaker than CLA. LA-metabolites thought to be weaker
agonistsofPPARγ.MKN28andColo320cellsexpressedboth
COX-2 and 15LOX-1. At least, relative high concentration
of LA might be metabolized dominantly by 15LOX-1,
which consequently provides antimetastatic eﬀect in these
cells.
Thus, LA and CLA suppress occurrence of cancer
metastasis and reduce existing metastatic tumors in animal
models. These ﬁndings encourage clinical usage of LA and
CLA for treatment of cancer metastasis.
6. EFFECT OF LA ON CANCER DORMANCY
A short-term treatment with LA or CLA induced apoptosis
in a dose-dependent manner through PPARγ activation as
described above. On the contrary, in a long-term contin-
uous treatment with adequate concentrations, LA induced
reversible cell growth-arrest in cancer cells that escaped from
apoptosis [62].
Cancer cell tumorigenicity in nude mice depends on
several factors in cancer cells themselves and their host.
To form macroscopical tumors, cancer cells must survive
in their host tissue against host immunity, and proliferate
with utilization of the host endothelial cells to make tumor4 PPAR Research
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Figure 1: Eﬀect of LA on growth inhibition in Ku-1 bladder cancer cells and DU145 prostate cancer cells by long-term treatment. Ku-7 cells
and DU145 cells were continuously treated with LA (100μg/mL) for the indicated period with weekly reseeding by 1 × 105 cells per well. If
cells were less than 1 ×105 cells per well, all cells were reseeded. Standard deviation of each cell number was less than 10% of the value.
vasculature. These steps are similar to those in metastasized
cancer cells on the metastasis targets [63]. If cancer cells do
not endure the attacks by host immunity, they cannot form
tumor. When they survive but not proliferate, the condition
resembles quiescent or static dormancy. When they survive
and proliferate but do not generate tumor vasculature, the
cancercellsstaymicroscopicalcellaggregation;thecondition
is to be an equivalent condition to tumor dormancy
[64].
In vitro cell growth was suppressed by 48-hour treat-
ment with LA in a dose-dependent manner in MKN28
and Colo320 cells. Continuous treatment with LA induced
quiescenceinbothcellsat5to7weeksaftertheLAtreatment.
The ﬁnding was also observed in Ku-7 bladder cancer
cells and DU145 prostate cancer cells (Figure 1). In LA-
induced quiescent cancer cells, protein production of Bcl-2
was increased, whereas Bak, EGFR, and vascular endothelial
growth factor (VEGF) levels were decreased [62]. These
alterationsmightbeassociatedwithinhibitionofcellgrowth,
angiogenesis, and apoptosis [65, 66], which explained well
the characteristics of LA-treated cancer cell aggregation.
These alterations of protein levels were the same as those
in cells treated with PPARγ ligands, toroglitazon, and CLA
[62]. The PPARγ expression was also decreased in quiescent
MKN28 and Colo320 cells by continuous treatment with LA.
The LA metabolites by 15LOX-1 activate mitogen-activated
protein kinase (MAPK) and increase PPARγ phosphory-
lation, but downregulate PPARγ activity [67]. Continuous
PPARγ phosphorylation might decrease PPARγ expression
by long-term LA treatment.
WhenMKN28andColo320cellswereinoculatedtonude
mice subcutaneous tissue, LA-induced quiescent MKN28
and Colo320 cells showed higher tumorigenicity than non-
treated cells in nude mice. In the contrary to the tumori-
genicity, LA-induced quiescent cancer cells showed 1/10
slower tumor growth than nontreated cells. LA withdrawal
after the inoculation provided regrowth in the cancer cells,
which subsequently grew into macroscopic tumors. LA-
induced quiescent cells were diﬀerent from growth-arrest
cells by aging or senescence, which are irreversible, and
refractory to growth factors [68].
In mice treated with LA weekly administration after the
inoculation, inoculated quiescent cancer cells did not form
macroscopical tumors. Histological examination revealed
less than 500μm-sized cancer-cell aggregations in the inoc-
ulation site. These cancer cell nests showed no proliferative
activity, no vascularity, and no immune cell inﬁltration
[62]. These features of the cancer cell nests were similar
to those in tumor dormancy status [64]. The dormant
cells expressed undetectable levels of PPARγ protein, which
suggests that inactivation of PPARγ might be associated with
tumor dormancy formation. In contrast, withdrawal of LA
might break the dormancy status in cancer cells. More-
over, PPARγ-negative dormant cells expressed increased
levels of nucleostemin. Nucleostemin possesses a role for
maintaining stemness [69, 70]. PPARγ inhibits Wnt and
LIF (leukemia inhibitory factor) signaling pathways, which
maintain pluripotency and self-renewal of stem cells [5, 71].
Downregulation of PPARγ might induce dediﬀerentiation
and stem cell/progenitor phenotype in cancer cells, which
might be associated with cancer dormancy and metastasis.
In this story, several possibilities are considered. Firstly,
LA-induced PPARγ d o w n r e g u l a t i o np r o v i d e ss t e m n e s si n
cancer cells. Secondly, LA-induced apoptosis abolishes
PPARγ-positivecancercellsandPPARγ-negativecancerstem
cell/progenitor cells remain. Thirdly, LA possesses direct
eﬀect on cancer stem niche. To conﬁrm the mechanism
underlying LA-induced cancer dormancy, further examina-
tion is requested to focus on the relation of PPARγ with
cancer stem cells.Hiroki Kuniyasu 5
7. CONCLUSION
In this article, we described that the dietary PPARγ ligands,
LA and CLA, are deeply involved in colorectal cancer
development and progression through PPARγ activation. LA
and CLA provide remarkable anticancer eﬀects by short-
termtreatment.Incontrast,long-termcontinuoustreatment
with LA induces quiescent and dormancy in cancer cells
with PPARγ downregulation. These conditions might be
associated with phenotypes of cancer stem cells/progenitor
cells. LA is a dietary factor to be taken from food everyday.
Cancer cells might be continuously exposed to various
concentrations of LA in human body. Taken together,
short-term administration of LA and CLA is an eﬀective
therapeutic tool for cancer metastasis. We are requested to
evaluate the eﬀect of dietary LA on cancer metastasis for
prevention of cancer metastasis and cancer dormancy.
NOMENCLATURE
PPAR: Peroxisome proliferator-activated receptor
LA: Linoleic acid
CLA: Conjugated linoleic acid
COX: Cyclooxygenases
LOX: Lipoxygenase
HODE: Hydroxyoctadecadienoic acid
OXO: Oxooctadecadienoic acid
PG: Prostaglandin
AOM: Azoxymethane
IL: Interleukin
NSAID: Nonsteroidal anti-inﬂammatory drug
NF: Nuclear factor
AP: Activator protein
ODN: Oligodeoxynucleotides
EGFR: Epidermal growth factor receptor
TGF: Transforming growth factor
VEGF: Vascular endothelial growth factor
MAPK: Mitogen-activated protein kinase
LIF: Leukemia inhibitory factor.
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